ArticleClinical and experimental medicine2026
Multi-omics profiling identifies ectopic olfactory receptors as putative drivers of tumor progression and prognostic indicators in clear cell renal cell carcinoma.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Olfactory receptors (ORs) are a subclass of G-protein-coupled receptors (GPCRs) that are primarily expressed in olfactory sensory neurons. Furthermore, ORs have recently been identified in the tumor microenvironment (TME) of various cancers, suggesting potential involvement for ORs in tumor progression. However, the roles of ORs in clear cell renal cell carcinoma (ccRCC), the most prevalent and aggressive subtype of kidney cancer, characterized by limited therapeutic response and a 5-year survival rate of only 10% in advanced stages, have yet to be elucidated. In this study, an integrative multi-omics analysis combining bulk transcriptomic profiles from The Cancer Genome Atlas (TCGA) and single-cell RNA- and ATAC-sequencing datasets from ccRCC patients to characterize the context- and cell-type-specific functions of ORs within the TME. Notably, ORs exhibited distinct, cell-type-specific expression profiles within ccRCC TME. OR51E1 was predominantly expressed in pericytes and correlated with vascular remodeling and angiogenic activity, whereas OR2T10 was enriched in malignant epithelial cells and associated with invasive and metastatic potential, with each OR being associated with resistance to therapeutic agents. In addition, OR-based prognostic modeling and tumor clustering both identified unfavorable prognostic signatures associated with poor patient outcomes and TME-related immunosuppression. These findings highlight ectopic OR networks as clinically relevant molecular features of ccRCC progression and position ORs as potential actionable biomarkers and potential therapeutic targets, offering new avenues for precision oncology in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.